Carlos Galvez is an Oncology physician affiliated with University of Illinois Chicago. OpenAlex indexes 40 publications with 365 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AbbVieProgram year20253 paymentsResearch$36,763openpaymentsdata.cms.gov ↗
- Bristol Myers SquibbProgram year20251 paymentResearch$11,900openpaymentsdata.cms.gov ↗
- Kite PharmaProgram year20251 payment
Services and research payments matched to this physician's NPI in CMS Open Payments. Meals, travel and gifts are counted in the company total and not listed here. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
33%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor33%Acyclovir100%Part D≥14 patientsMetabolism & gastrointestinal
27.3%Corticosteroid27.3%Prednisone100%Part D<11 patientsMusculoskeletal
14.8%Xanthine oxidase inhibitor14.8%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- AML-1373: Epigenetic Gene Expression Profiling as a Predictor of Ex Vivo Venetoclax Sensitivity in Acute Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia
2026 - POSTER: AML-1373: Epigenetic Gene Expression Profiling as a Predictor of Ex Vivo Venetoclax Sensitivity in Acute Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia
2026 - Age and the genomic landscape of AML in precision oncology: An analysis using ASH HematOmics Program.
Journal of Clinical Oncology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Jerry Krishnan, MD
University of Illinois Chicago
John Daugirdas, MD
University of Illinois Chicago
Niranjan Karnik, MD
University of Illinois Chicago
Oana Danciu, MD
University of Illinois Chicago
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”